NovaBay Pharmaceuticals Files 8-K
Ticker: NBY · Form: 8-K · Filed: Apr 22, 2024 · CIK: 1389545
Sentiment: neutral
Topics: 8-K, financial-reporting, regulatory-filing
TL;DR
NovaBay filed a routine 8-K, no major news.
AI Summary
NovaBay Pharmaceuticals, Inc. filed an 8-K on April 22, 2024, to report other events and financial statements. The filing does not contain specific details about material events or financial performance beyond the standard reporting requirements.
Why It Matters
This 8-K filing indicates NovaBay Pharmaceuticals is fulfilling its regulatory reporting obligations by submitting standard financial statements and other required disclosures.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for reporting financial statements and other events, with no indication of significant negative developments.
Key Numbers
- 001-33678 — SEC File Number (Identifies the company's filing history with the SEC.)
- 68-0454536 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- NovaBay Pharmaceuticals, Inc. (company) — Registrant
- April 22, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 2000 Powell Street, Suite 1150 (address) — Principal Executive Offices
- Emeryville, CA 94608 (address) — Principal Executive Offices Location
FAQ
What is the primary purpose of this 8-K filing for NovaBay Pharmaceuticals?
The primary purpose is to report 'Other Events' and to file 'Financial Statements and Exhibits' as of April 22, 2024.
What is the date of the earliest event reported in this filing?
The date of the earliest event reported is April 22, 2024.
In which state is NovaBay Pharmaceuticals, Inc. incorporated?
NovaBay Pharmaceuticals, Inc. is incorporated in Delaware.
What is the principal executive office address for NovaBay Pharmaceuticals?
The principal executive office is located at 2000 Powell Street, Suite 1150, Emeryville, CA 94608.
Does this 8-K filing disclose any specific material events or financial results?
This filing is a standard 8-K for reporting purposes and does not, on its face, disclose specific material events or detailed financial results beyond the requirement to file financial statements and exhibits.
Filing Stats: 671 words · 3 min read · ~2 pages · Grade level 12.2 · Accepted 2024-04-22 06:04:24
Key Financial Figures
- $0.01 — Registered Common Stock , par value $0.01 per share NBY NYSE American Indicat
Filing Documents
- nby20240420_8k.htm (8-K) — 26KB
- ex_657449.htm (EX-99.1) — 13KB
- pic1.jpg (GRAPHIC) — 38KB
- pic2.jpg (GRAPHIC) — 102KB
- pic3.jpg (GRAPHIC) — 84KB
- pic4.jpg (GRAPHIC) — 70KB
- pic5.jpg (GRAPHIC) — 103KB
- pic6.jpg (GRAPHIC) — 75KB
- pic7.jpg (GRAPHIC) — 46KB
- pic8.jpg (GRAPHIC) — 94KB
- pic9.jpg (GRAPHIC) — 68KB
- pic10.jpg (GRAPHIC) — 103KB
- pic11.jpg (GRAPHIC) — 91KB
- pic12.jpg (GRAPHIC) — 100KB
- pic13.jpg (GRAPHIC) — 111KB
- pic14.jpg (GRAPHIC) — 115KB
- pic15.jpg (GRAPHIC) — 97KB
- pic16.jpg (GRAPHIC) — 81KB
- pic17.jpg (GRAPHIC) — 74KB
- pic18.jpg (GRAPHIC) — 44KB
- pic19.jpg (GRAPHIC) — 72KB
- pic20.jpg (GRAPHIC) — 14KB
- pic21.jpg (GRAPHIC) — 82KB
- pic22.jpg (GRAPHIC) — 70KB
- 0001437749-24-012606.txt ( ) — 2560KB
- nby-20240422.xsd (EX-101.SCH) — 3KB
- nby-20240422_def.xml (EX-101.DEF) — 11KB
- nby-20240422_lab.xml (EX-101.LAB) — 15KB
- nby-20240422_pre.xml (EX-101.PRE) — 11KB
- nby20240420_8k_htm.xml (XML) — 3KB
01
Item 8.01 Other Events On April 22, 2024, NovaBay Pharmaceuticals, Inc. (the "Company") issued a corporate update presentation containing an update on the Company's operations, particularly in regards to driving sales and executing on the Company's business strategy. A copy of the presentation is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated by reference herein.
Forward-Looking Statements
Forward-Looking Statements This report contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, but not limited to, statements that are based upon management's current expectations, assumptions, estimates, projections and beliefs. The use of words such as, but not limited to, "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "project," "should," "target," "will," or "would" and similar words or expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding the Company's future operations and business strategy. These statements involve risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Other risks relating to the Company's business, including risks that could cause results to differ materially from those projected in the forward-looking statements in this report, are detailed in the Company's latest Form 10-K filing with the SEC, especially under the heading "Risk Factors." The forward-looking statements in this report speak only as of this date, and the Company disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits . Exhibit No. Description 99.1 Corporate Update Presentation, released April 22, 2024 104 Cover Page Interactive Date File (embedded with the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NovaBay Pharmaceuticals, Inc. By: /s/ Justin Hall Justin Hall Chief Executive Officer and General Counsel Dated: April 22, 2024